Who are Syndax Pharmaceuticals, Inc.'s main suppliers?

Syndax Pharmaceuticals, Inc. (SNDX) key suppliers include: UCB-BIOPHARMA-SRL, Royalty Pharma plc, Royalty Pharma plc, VITAE-LICENSE-AGREEMENT, Actinium Pharmaceuticals, Inc.. View the full supplier network at chainsifter.com/chain/SNDX.

Who are Syndax Pharmaceuticals, Inc.'s major customers?

Syndax Pharmaceuticals, Inc. (SNDX) key customers include: REVUFORJ, NIKTIMVO. View the full customer network at chainsifter.com/chain/SNDX.

What sector is Syndax Pharmaceuticals, Inc. in?

Syndax Pharmaceuticals, Inc. (SNDX) operates in the general sector. ChainSifter tracks its verified supply chain relationships including suppliers, customers, and strategic partners.

SNDX Supply Chain: Syndax Pharmaceuticals, Inc. Supplier List & 10 Relationships

5Suppliers

2Customers

3Debt Items

20Related Chains

Syndax Pharmaceuticals, Inc. Suppliers

Ticker	Name	Confidence	Evidence
UCB-BIOPHARMA-SRL	UCB-BIOPHARMA-SRL	92%	In 2016, the Company entered into a license agreement, or the UCB License Agreement, as amended from time to time, with UCB Biopharma Sprl, or UCB, under which UCB granted to the Company a worldwide,…
RPRX	Royalty Pharma plc	90%	the Purchase and Sale Agreement provides that if certain events of default occur, including certain bankruptcy events or certain termination events with respect to the Company’s license agreement wit…
RPRX	Royalty Pharma plc	90%	Reciprocal relationship from RPRX graph: Reciprocal relationship from SNDX graph: the Purchase and Sale Agreement provides that if certain events of default occur, including certain bankruptcy events…
VITAE-LICENSE-AGREEMENT	VITAE-LICENSE-AGREEMENT	85%	As of the date of the Vitae License Agreement, the asset acquired had no alternative future use nor had it reached a stage of technological feasibility
ATNM	Actinium Pharmaceuticals, Inc.	72%	Reciprocal relationship from ATNM graph: Reciprocal relationship from SNDX graph: Reciprocal relationship from ATNM graph: Reciprocal relationship from SNDX graph: Reciprocal relationship from ATNM g…

Syndax Pharmaceuticals, Inc. Customers

Ticker	Name	Confidence	Evidence
REVUFORJ	REVUFORJ	80%	We are leading the commercialization and further development of revumenib and working closely with our collaboration partner, Incyte, on the commercialization and further development of axatilimab
NIKTIMVO	NIKTIMVO	75%	the first United States sale of Revuforj in its second indication

Syndax Pharmaceuticals, Inc. Debt Obligations

Instrument	Description	Confidence	Evidence
SNDX-DEBT-12638	Xbrl Convertible	90%	xbrl convertible detail from xbrl 2016-12-31.
SNDX-DEBT-12637	Warrants outstanding: 0.0001	90%	xbrl warrant detail from xbrl 2019-03-31.
SNDX-DEBT	Debt stack $345.4M	90%	Market cache reports total debt of $345.4M.

Syndax Pharmaceuticals, Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Syndax Pharmaceuticals, Inc..

Syndax Pharmaceuticals, Inc. Ownership

Holder	Name	Confidence	Evidence
SNDX-OWNER-GOLDMAN-SACHS-GROUP-INC	GOLDMAN SACHS GROUP INC	90%	13F overlay lists GOLDMAN SACHS GROUP INC as top holder; 246 tracked holders.

Syndax Pharmaceuticals, Inc. Extended Supply Chain Network

Ticker	Name	Chain Index	Hops	Relationship Types
TKPHF	Takeda Pharmaceutical Company Limited	100.00	2
PRLD	Prelude Therapeutics Incorporated	100.00	2
ATNM	Actinium Pharmaceuticals, Inc.	100.00	1	['supplier']
MGNX	MacroGenics, Inc.	100.00	2
LLY	Eli Lilly and Company	100.00	2
RPRX	Royalty Pharma plc	100.00	1	['supplier']
SWKH	SWK Holdings Corp	50.00	2
KURA	Kura Oncology, Inc.	50.00	2
PRTC	PureTech Health plc	50.00	2
RVMD	Revolution Medicines, Inc.	50.00	2
MNPR	Monopar Therapeutics Inc.	50.00	2
MRK	Merck & Co., Inc.	50.00	2
TLX	Telix Pharmaceuticals Limited	50.00	2
PTCT	PTC Therapeutics, Inc.	50.00	2
NERV	Minerva Neurosciences, Inc.	50.00	2
JNJ	Johnson & Johnson	50.00	2
NUVL	Nuvalent, Inc.	50.00	2
TAKEDA	TAKEDA	50.00	2
ORANY	ORANGE	50.00	2
CNSP	CNS Pharmaceuticals, Inc.	50.00	2

Syndax Pharmaceuticals, Inc. Supply Chain